DM of ISED Meeting with COVID-19 Vaccine Task Force

Meeting Objective: Kick-off meeting of the Vaccine Task Force, at which the co-chairs and government members will lead discussion on Task Force mandate, procedures and next steps.

Desired Outcome: Awareness among members of Task Force mandate and priorities and procedures for security and conflict of interest, and agreement on next steps including the next meeting of the Task Force to review project proposals, biomanufacturing and timelines for the provision of advice.

Key Issues / Priority Discussion Items: Task Force mandate and priorities

ISED / Canadian Position: Interest in receiving advice from Task Force in short-order on prioritizing SIF proposals and advice on biomanufacturing vaccine-related procurement and long-lead time investments.

Organization Position: As this is the first meeting of the Task Force, members are expected to have questions about the mandate, expectations on their time, and deliverables.

Key Questions:

- Have you given thought to how you will organize the streams of work relative to the expertise you have on the Task Force, for example, industry expertise on biomanufacturing related topics?

- Have you worked out how you will be connecting to the Therapeutics Advisory Group on matters of common consideration, e.g., manufacturing, how to make best use of the $600 million between the multiple priorities?

Biography: see attached for biographies of all external members of the Task Force

Organization Profile: see attached Terms of Reference for the Task Force

Key Issues:

- The first meeting of the Task Force will be an important opportunity to make clear the priorities, expectations and constraints of the Task Force.

- The Task Force has a broad and potentially expansive mandate that must be balanced with the need for immediate advice on discrete project proposals and purchasing issues. Focusing members on addressing urgent deliverables will be key, with the understanding that there will be opportunities for discussion and advice on broader strategic issues to follow.

- There are a number of administrative issues that will have to be addressed with Task Force members, including conflict of interest procedures, confidentiality expectations, file sharing, cybersecurity and meeting management. Discussion of these issues is expected to comprise a significant portion of the first meeting.

- Reinforcing that given our role, ISED is available to provide analysis and information, as they require, in particular on manufacturing. Additional resources will be available to support their work as they need it.

POINTS TO REGISTER

Opening Remarks

Point One:

- [redacted]
- [redacted]

Point Two:

- [redacted]
- [redacted]

Point Three:

- [redacted]
- [redacted]

Concluding Remarks – Thank You

If any questions on mandate:

From the Terms of Reference

(2)The Task Force is to provide advice to the Government of Canada on COVID-19 vaccines, which can include the following:

- prioritizing vaccine projects seeking support for activities in Canada;
- non-Canadian vaccine candidates of interest to attract into or partner with Canada;
- optimizing the tools needed for vaccine development (e.g., assays and animal models);
- effective R&D and supply chain coordination for COVID-19 vaccine projects;
- solutions to domestic manufacturing of the most promising COVID vaccines; and,
- opportunities to enhance business connectivity globally to secure access to vaccines with key commercial sponsors.

COVID-19 Vaccine Task Force

TERMS OF REFERENCE

1. PURPOSE:

(1) The COVID-19 Vaccine Task Force ("Task Force") will be responsible for providing advice to the Government of Canada on COVID-19 vaccines, drawing on their expertise on vaccine development, commercialization and manufacturing. This Terms of Reference is comprised of four sections that outline the purpose, mandate, governance structure and procedural items of the Task Force.

2. MANDATE

(2) The Task Force mandate is to provide advice to the Government of Canada on COVID-19 vaccines, which can include the following:

- prioritizing vaccine projects seeking support for activities in Canada;
- non-Canadian vaccine candidates of interest to attract into or partner with Canada;
- optimizing the tools needed for vaccine development (e.g., assays and animal models);
- effective R&D and supply chain coordination for COVID-19 vaccine projects;
- solutions to domestic manufacturing of the most promising COVID vaccines; and,
- opportunities to enhance business connectivity globally to secure access to vaccines with key commercial sponsors.

3. GOVERNANCE

3.1. Structure and composition

(3) The Task Force will have up to 18 members, including two Co-chairs and 4 ex-officio members.

(4) The Task Force will include vaccine and immunology experts and industry leaders who have proven ability in vaccine development and commercialization.

(5) The Task Force will provide advice to the Ministers of Innovation, Science and Industry and Health.

(6) The Deputy Minister of Innovation, Science and Economic Development Canada, the Deputy Minister of Health Canada, the President of the Public Health Agency of Canada and the Chief Science Advisor will be ex officio members.

(7) Task Force members are appointed as individuals and not as representatives of their organizations.

(8) The Task Force can, at their discretion, consult with additional subject matter experts on an as-needed basis.

3.2. Confidentiality and Conflict of Interest

(9) Task Force members will sign confidentiality and conflict of interest agreements. Furthermore, if at anytime a member becomes aware of a potential project in which he/she has a personal financial interest, it will be disclosed to the Co-chairs and to the Government of Canada representative who shall have the right to ask the member to formally recuse themselves from participating in discussions related to that project.

(10) The Task Force will ensure that advice received from additional subject matter experts will not result in any conflict of interest, and that there is full disclosure to the Government of Canada representative of any potential real or perceived conflicts of interest, where known.

(11) Documents or information obtained while serving on the Task Force should be used only in the context of fulfilling the duties and mandate of the Task Force. Any documents or information obtained through a meeting of the Task Force will be kept strictly confidential by the member, unless prior approval to disclose is obtained in writing from the Government of Canada representative.

(12) In dealings with the media, public forums, and in inter-personal conversation, members will show sensitivity and discretion in any statement made regarding the activities of the Task Force, and will refrain from disclosing any information shared with or by Task Force members.

3.3. Timing and Deliverables

(13) The Task Force will be in place for a period of at least 12 months, subject to extension at the discretion of the Government of Canada, and will meet on an as-needed basis.

(14) The Task Force will determine its own meeting schedule in order to meet the direction and deadlines provided by the Government of Canada's designated representative.

(15) The advice of the Task Force, and any supporting products provided to the Government of Canada by members, will remain the property of the individual members and held in confidence by the Government of Canada.

(16) Decisions on the advice provided will be made on a consensus basis. Consensus will have been reached when there is agreement to the extent that all participants are willing to support the outcome or use it as a basis for further discussion. The outcome must show how dissenting points of view were accommodated and record what has and has not been agreed upon. Ex-officio members may participate in discussions but will not participate in the decision-making related to the provision of advice from the Task Force.

4. PROCEDURAL ITEMS

4.1. Member Responsibilities

(17) All Participants will:

- agree to act in "good faith" in all aspects of the process;

- commit to fully explore issues, searching for solutions in a problem solving atmosphere; and,
- agree to make a good faith attempt to share information in matters related to the shared decision-making process.

(18) It is the responsibility of the Co-chairs to:

- Approve meeting agendas in advance of meetings, working with the Secretariat;
- Encourage the active participation of all members;
- Monitor progress on action items between meetings;
- Establish and chair sub-working groups, where appropriate; and,
- Chair meetings of the Task Force.

(19) It is the responsibility of each Task Force member to:

- Stay current with information and the progress of discussions;
- Attend each meeting, to the best of their ability.

4.2. Secretariat

(20) Government of Canada officials will be provided for administrative and technical support of the Task Force. The Secretariat will be housed at the National Research Council of Canada. The primary role of the Secretariat will be to coordinate and support the work of the Task Force. This includes:

- Design and delivery of meeting agendas;
- Development and monitoring of the workplan; and,
- Organization and facilitation of meetings.

The Secretariat will make every reasonable effort to gather data and information and draft materials to support the Task Force in fulfilling its mandate.

4.3. Technical and Substantive Information

(21) The Secretariat, provided by the Government, will provide support for the meetings in the form of recording notes and dispersing information.

(22) All efforts will be taken by the Government of Canada to provide all information requested of them except if covered by Cabinet confidentiality or privacy restrictions, within the limits of government budget and staffing power.

(23) Documents for the Task Force will be password-protected and provided to the Secretariat through a secure file sharing site.

(24) Tentative or sensitive data or other information will be respected as such, by both the Task Force and the Government of Canada.

4.4. Meetings

(25) Meetings will be held on an as needed basis, at the discretion of the Co-chairs. Meetings will be held by teleconference to respect physical distancing requirements and avoid non-essential travel.

(26) To ensure the effectiveness of the meetings, the Secretariat will forward to all participants prior to the meeting: an agenda, a record of decision from previous meetings, background information where possible and a clear statement of the objectives for the meeting.

(27) All meetings will be conducted according to the following ground rules:

1. Meetings shall begin promptly at the time indicated on the agenda.
2. The meetings shall be chaired in a manner that:
   - Ensures that time is allotted for discussion of each item on the agenda;
   - A balance of views and discussion takes place on each issue;
   - All participants have an opportunity to participate equally in discussion on a topic.
3. The chairing of the meetings will alternate between the two Co-chairs, according to a schedule to be set out in the work plan.
4. The meeting chair shall ensure that the manner in which each topic on the agenda is dealt with is clearly summarized at the conclusion of that discussion.
5. The meeting chair has the responsibility to facilitate meetings. However, members have the opportunity to make recommendations to the Chair and Secretariat on alternative facilitation.

(28) Meeting summaries shall be prepared and distributed in a timely manner under the direction of the Secretariat.

4.5. Public Communication and the Media

(29) The following procedure will be followed with respect to public communication:

- The Secretariat shall be the government contact for all media inquiries;
- Media releases will be agreed to by consensus prior to release;
- In the event that members wish to respond to media inquiries, they are to speak from their own perspective and not from that of the Task Force; and,
- Audio and visual recording will not be permitted at Task Force meetings.

4.6. Process to Withdraw

(30) Any member considering withdrawing from the Task Force will be asked to notify the Co-chairs and the Secretariat as soon as possible. The member will continue to be bound by the Terms of Reference, particularly with respect to confidentiality of information shared.

COVID-19 Vaccine Task Force Member List

Joanne Langley (Co-Chair)	2
J. Mark Lievonen, C.M. (Co-Chair)	3
Alan Bernstein	4
Robert Brunham	5
Michel De Wilde	6
[redacted]	7
Bartha Maria Knoppers	8
Gary Kobinger	9
Christopher Procyshyn	10
Benjamin Rovinski	11
Lorne Tyrrell	12
Sylvia van Drunen Littel-van den Hurk	13
André Veillette	14
EX-OFFICIO MEMBERS:	15
Stephen Lucas	15
Simon Kennedy,	15
Tina Namiesniowski	15
Mona Nemer	15

JOANNE LANGLEY (CO-CHAIR)

Professor of Pediatrics and Community Health and Epidemiology,
Dalhousie University Faculty of Medicine,
Halifax, NS

Dr. Langley is a pediatric infectious disease physician based at the IWK Health Centre and the Canadian Center for Vaccinology (CCfV) at Dalhousie University. She is the Associate Director for Vaccine Evaluation Group at CCfV, and works with collaborators in academia, public health, industry, and non-governmental organizations to conduct phase 1 through 4 trials. She holds the CIHR-GSK Chair in Pediatric Vaccinology at Dalhousie University. She is an active investigator in the Canadian Immunization Research Network (CIRN) and is the lead investigator for its Clinical Trials Network (CTN). Dr. Langley's work also focuses on vaccine policy and evidence-based decision making in immunization programs. She is a member of the COVID-19 Science Expert Panel for the Chief Science Advisor of Canada, and a former member of the Canadian Task Force on Preventive Health Care and Canada's National Advisory Committee on Immunization (Chair, 2007-2011), and serves as an advisor on several immunization decision making expert groups.

https://medicine.dal.ca/departments/department-sites/pediatrics/our-people/our-faculty/joanne-langley.html

Twitter: @jmllhfx

J. MARK LIEVONEN, C.M. (CO-CHAIR)

Mark Lievonen is the Principal of JML Advisory Services and the former President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. He served as Chair of the Board of Directors of BIOTECanada, Rx&D (now Innovative Medicines Canada), the Ontario Genomics Institute, the Markham Stouffville Hospital Foundation and the Centre for the Advancement of Health Innovation, as Vice-Chair of the Ontario Institute for Cancer Research, and as a member of the Board of Oncolytics Biotech, Acerus Pharmaceuticals, Quest PharmaTech, the Public Policy Forum and York University. Currently, he is a member of the Board of OncoQuest Pharmaceuticals Inc., Biome Grow Inc. and the Gairdner Foundation.

Mark was appointed to the Order of Canada, named a Chevalier de l'Ordre National de Merite by the Government of France, and inducted into the Canadian Healthcare Marketing Hall of Fame. He has received Lifetime Achievement Awards from Life Sciences Ontario and the Pharmaceutical Sciences Group, and the Canada Medal from The Chemical Institute of Canada.

Mark holds a BBA in accounting and a MBA in finance and marketing from the Schulich School of Business, and received a Honourary Doctor of Laws from York University. He is a Chartered Professional Accountant and was elected a Fellow of the Institute of Chartered Accountants of Ontario.

ALAN BERNSTEIN



President and CEO, CIFAR

Alan became CIFAR's President and Chief Executive Officer in May 2012. He was previously executive director of the Global HIV Vaccine Enterprise in New York, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine.

From 2000 to 2007, he served as the inaugural president of the Canadian Institutes of Health Research (CIHR), Canada's federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada.

After receiving his PhD from the University of Toronto, and following postdoctoral work at the Imperial Cancer Research Fund in London, Alan joined the Ontario Cancer Institute. In 1985, he joined the Samuel Lunenfeld Research Institute, was named its Associate Director in 1988 and Director of Research from 1994 to 2000.

Author of over 225 scientific publications, Alan has made extensive contributions to the study of stem cells, blood cell formation (hematopoiesis) and cancer. He chairs or is a member of advisory and review boards in Canada, the U.S., U.K., Italy and Australia. Alan also served as co-chair of the Scientific Advisory Committee for Stand Up 2 Cancer Canada with Phillip A. Sharp.

A much sought after science advisor in countries around the world, his contributions to science have been recognized with numerous awards and honorary degrees, including Officer of the Order of Canada, Order of Ontario, induction into the Canadian Medical Hall of Fame, and the 2017 Henry Friesen International Prize in Health Research.

https://www.cifar.ca/bio/alan-bernstein

ROBERT BRUNHAM

Head of the Vaccine Research Laboratory at BCCDC
Professor of medicine, UBC

Dr. Brunham holds a University of Washington post-doctoral fellowship in infectious disease and has a medical degree from UBC.

He has received international recognition and awards for his contributions to the field of infectious diseases prevention. He was the 2004 recipient of the prestigious Thomas Parran Award from the American Sexually Transmitted Disease Association for his long and distinguished contributions in research and was the 2005 co-recipient of the CIHR Partnership Award for his co-leadership in the SARS Accelerated Vaccine Initiative.

http://www.bccdc.ca/our-research/people/robert-brunham

MICHEL DE WILDE

Former Senior Vice President, Research & Development, Sanofi Pasteur

Michel De Wilde has a long career in Vaccine Research and Development. He currently consults for the vaccine community.

From 2001 to June 2013, Michel De Wilde was Senior Vice President, Research & Development, at Sanofi Pasteur.

While at Sanofi Pasteur, Michel drove the development and licensure by the FDA and other Regulatory bodies of a number of products. Michel was also instrumental in driving the acquisition of and defining the integration model for two biotech companies: Acambis and VaxDesign.

Prior to joining Sanofi Pasteur, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility to become Vice President, Research & Development. De Wilde has played a key role as a research scientist in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK's Malaria vaccine.

Michel De Wilde received is Ph.D. in Biochemistry in 1976, from the Free University of Brussels.

Twitter: @Micheldewilde

Page 14

is withheld pursuant to section

est retenue en vertu de l'article

19(1)

of the Access to Information Act

de la Loi sur l'accès à l'information

BARTHA MARIA KNOPPERS

Professor, Canada Research Chair in Law and Medicine and Director of the Centre of Genomics and Policy of the Faculty of Medicine at McGill University

Bartha Maria Knoppers, PhD (Comparative Medical Law), is a Full Professor, Canada Research Chair in Law and Medicine and Director of the Centre of Genomics and Policy of the Faculty of Medicine at McGill University. She was the Chair of the Ethics and Governance Committee of the International Cancer Genome Consortium (2009-2017). She is currently Chair of the Ethics Advisory Panel of WADA (2015-), and is Co-Chair of the Regulatory and Ethics Workstream of the Global Alliance for Genomics and Health (2013-). In 2015-2016, she was a member of the Drafting Group for the Recommendation of the OECD Council on Health Data Governance and gave the Galton Lecture in November 2017. She holds four Doctorates Honoris Causa and is a Fellow of the American Association for the Advancement of Science (AAAS), the Hastings Center (bioethics), the Canadian Academy Health Sciences (CAHS), and, the Royal Society of Canada. She is also an Officer of the Order of Canada and of Quebec, and was awarded the 2019 Henry G. Friesen International Prize in Health Research and was appointed to the International Commission on the Clinical Use of Human Germline Genome Editing.

http://www.genomicsandpolicy.org/en/team-member/no9

GARY KOBINGER

Professor and Director of the Infectious Disease Research Centre, Université Laval
Quebec City, QC

Gary Kobinger obtained his Ph.D. from the University of Montreal in 1998 before completing a post-doctoral fellowship at the University of Pennsylvania. In March 2005, Gary was recruited by the Public Health Agency of Canada where he was from 2008 to 2016 the Chief of the Special Pathogens Biosafety Level 4 program at the National Microbiology Laboratory. He is now professor and the Director of the Infectious Disease Research Centre at the Université Laval and has an appointment of associate professor at the University of Manitoba and adjunct professor at the University of Pennsylvania.

Gary has been granted several awards including the Faculty Teaching Award from the University of Manitoba, the 2014 Gully award, the 2015 scientists of the year award from Radio Canada (CBC), the Order of Manitoba and the Meritorious Service Cross (civil division) of the Governor General of Canada in 2016, the Manning principal award in 2017 and the Governor General of Canada Innovation award in 2018. Gary has co-authored over 300 peer-reviewed scientific manuscripts, and has participated to many advisory boards to academic, national and international funding agencies, departments of national defenses, and the World Health Organization (WHO) concerning research on high consequence pathogens and the development of new public health policies and recommendations. His work presently focuses on developing and testing new vaccine platforms and immune treatments against pathogens of high consequences to global public health.

In 2013-2020, 60 minutes, National Geographic, BBC Horizon, NOVA, France 2, PBS, CBC, RC and others featured the leading work on successful treatment of Ebola infection that was developed by Gary and his team and the VSV-based Ebola vaccine to which he has also contributed to bringing to clinical trials.

https://www.who.int/emergencies/diseases/strategic-and-technical-advisory-group-for-infectious-hazards/members/biographies/en/index5.html

http://www.crchudequebec.ulaval.ca/recherche/chercheurs/gary-kobinger/

CHRISTOPHER PROCYSHYN



CEO, Vanrx PharmaSystems

Chris Procyshyn is the Chief Executive Officer of Vanrx Pharmasystems, a founder, and member of its Board of Directors. With over twenty-five years' experience in the pharmaceutical industry, Chris has led teams in the development of complex injectable products in the fields of ophthalmology, oncology and reproductive health. Globally experienced, he has negotiated the implementation of new technologies with many of the major regulatory agencies. Previously with QLT Inc., a pioneering Canadian biopharmaceutical company, Chris led the Manufacturing, Engineering and Process Sciences groups in the development of many advanced pharmaceutical processes and their implementation into manufacturing facilities in multiple countries. Chris is a past Vice President of the ISPE Pacific Northwest Chapter, and is a graduate of the University of Saskatchewan with a Bachelor of Science degree in Microbiology.

https://ispe.org/people/chris-procyshyn

BENJAMIN ROVINSKI

Managing Director, Lumira Ventures
Toronto, ON

With over 30 years of investment, operational, managerial and research experience in the healthcare industry, Beni has helped build life sciences companies at all stages of development. Known both as a senior scientist and as an achievement-oriented executive, with demonstrated success in strategic planning, drug development, and operational management of global multifunctional teams, Beni has established a sound reputation built on his clarity of objectives, leadership, judgement and integrity.
Beni's investment focus is primarily on North American mid- to late-stage private and public companies involved in drug discovery and development, biological and small molecule therapeutics, drug delivery, specialty pharmaceuticals, genomics, proteomics and diagnostic devices.

With a proven track record of delivering results both as a senior scientist and a business executive, Beni has held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur (formerly Aventis Pasteur) where he was a senior scientist and director of molecular virology, with a particular focus in the areas of virology, vaccine development, recombinant protein production, and functional genomics. While at Aventis, Beni led global research and development programs in the areas of HIV/AIDS and therapeutic cancer vaccines, bringing several of them through to clinical stage.

Beni is fluent in English, French and Spanish. He has published over 25 scientific articles and reviews and is the recipient of 32 issued patents. Beni's current and past board roles and investment responsibilities include: Antiva Biosciences, Antios Therapeutics, Aurinia Pharmaceuticals (NASDAQ: AUPH), Bright Angel Therapeutics, G1 Therapeutics (Nasdaq: GTHX), KAI Pharmaceuticals (acquired by Amgen); Morphotek (acquired by Eisai), and Notch Therapeutics. Beni also serves on the Board of Directors of Life Sciences Ontario, Ontario Genomics, and he volunteers for various personal career mentoring programs targeting young adult entrepreneurs.

https://www.lumiraventures.com/team-member/beni-rovinski-phd/

LORNE TYRRELL



Founding Director, Li Ka Shing Institute of Virology; Distinguished University Professor, University of Alberta; Professor, Department of Medical Microbiology & Immunology Edmonton, AB

D. Lorne Tyrrell, OC, AOE, MD, PhD, FRCPC, FRSC, FCAHS holds the GSK Chair in Virology in the Department of Medical Microbiology and Immunology at the University of Alberta. He is also the Founding Director of the Li Ka Shing Institute of Virology. He has focused his research since 1986 on viral hepatitis. His work on the development of antiviral therapy was supported by CIHR and Glaxo Canada. It resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection – lamivudine – in 1998. Today, lamivudine is licensed in over 200 countries worldwide for the treatment of HBV. He has also been involved in the establishment of a biotech company—KMT Hepatech Inc. based on the first non-primate animal model for HCV in 2003. KMT Hepatech was sold to PhoenixBio in 2017.

Dr. Tyrrell was the Dean of the Faculty of Medicine and Dentistry from 1994-2004. Since leaving the Deanship in 2004, Dr. Tyrrell has held a number of important board positions in healthcare in Alberta and Canada. These include the Chair of the Board of the Institute of Health Economics (2004-2018) and the Chair of the Board of the Health Quality Council of Alberta (2003-2012). He was the Chair of the Gairdner Foundation Board (2009-2019) and serves on the Research Advisory Council for the Canadian Institute for Advanced Research, was appointed to the Science Advisory Board to Health Canada, and chaired the Board of the Alberta Precision Laboratories (2018-2019).

For his studies on viral hepatitis, Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation (2000), the Alberta Order of Excellence (2000), Officer of the Order of Canada (2002), Fellow of the Royal Society (2004), FNG Starr Award of the Canadian Medical Association (2004), and the Principal Award of the Manning Foundation (2005). He was awarded the University Distinguished Professorship at the University of Alberta and was inducted into the Canadian Medical Hall of Fame in April 2011. In 2015, he was awarded the Killam Prize in Health Sciences.

SYLVIA VAN DRUNEN LITTEL-VAN DEN HURK

Professor, Biochemistry, Microbiology & Immunology, College of Medicine, University of Saskatchewan.
Program Manager, Viral Pathogenesis and Vaccine Development, VIDO-InterVac, University of Saskatchewan.

Dr. Sylvia van den Hurk received her B.Sc. and MSc at the University of Wageningen in the Netherlands and a PhD at University of Saskatchewan. Her research interests are focused on disease control and virus-host interactions. Current projects include respiratory syncytial virus - host interactions, development of RSV and parainfluenzavirus-3 vaccines, and herpesvirus pathogenesis. Dr. van den Hurk has published over 225 peer-reviewed manuscripts, review articles, and book chapters, and holds/contributed to 12 patents. She has mentored over 60 students and post-doctoral fellows. Her research is/has been funded by provincial, national (Canadian Institutes for Health Research, Natural Sciences and Engineering Council) and international (Bill and Melinda Gates Foundation) granting agencies. Dr. van den Hurk has served as reviewer in several national and international grant review panels. She is Associate Editor for the journal Vaccine, and is on the editorial board of the journal npj Vaccines (Nature Publishing).

https://www.vido.org/team/science-management/sylvia-van-drunen-littel-van-den-hurk

https://medicine.usask.ca/profiles/biochemistry-microbiology-immunology/sylvia-vandenhurk.php#About

ANDRÉ VEILLETTE

Professor, Department of Medicine, Université de Montréal; Director, Molecular Oncology Research Unit, IRCM

After completing his medical training in 1981 at the Université Laval, Dr. André Veillette did a residency in Internal Medicine at the Montreal General Hospital and basic research training in immunology at the National Cancer Institute in the United States. He joined the Faculty of Medicine at McGill University in September 1989 and, in 1999, relocated his laboratory to the Montréal Clinical Research Institute (IRCM) and the Université de Montréal.

Dr. Veillette's research contributions have been recognized at the national level. In 1992, he won the Young Investigator Award from Bio-Méga Boehringer-Ingelheim. Dr. Veillette subsequently received in 1994 the William E. Rawls Award of the National Cancer Institute of Canada. In 1999, he was awarded the Young Investigator Award "André Dupont" from the Club de Recherches Cliniques du Québec. In 2000, Dr. Veillette was the recipient of the Merck Frosst Prize. In 2007, he received the Leo-Pariseau Prize. Dr. Veillette was also awarded a Medical Research Council of Canada Scholarship and a Canadian Institutes of Health Research Scientist Award. In 2008, Dr. Veillette was elected Member of the Royal Society of Canada.

Dr. Veillette's accomplishments have also been acknowledged at the international level, participating in a number of Editorial Boards. As a reflection of his contribution to basic research, Dr. Veillette was elected a Member of the American Society for Clinical Investigation in 1995. Furthermore, in 2007, he was awarded an International Scholar Award from the Howard Hughes Medical Institute (HHMI).

Twitter: @AndreVeillette

EX-OFFICIO MEMBERS:

STEPHEN LUCAS
Deputy Minister of Health

SIMON KENNEDY,
Deputy Minister of Innovation, Science and Economic Development

TINA NAMIESNIOWSKI
President, Public Health Agency of Canada

MONA NEMER
Chief Science Advisor